Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy
Source abstract
Abstract
Herein, we investigated the biological uptake, distribution, and radiopharmaceutical potential of a novel molecule based on 2-hydroxyethyl methacrylate (HEMA) and anilinephtalein (APH) in the metabolism of Albino Wistar rats. In order to achieve this, we synthesized APH using organic synthesis methods and copolymerized APH with HEMA using a common polymerization method, surfactant-free emulsion polymerization. In the presence of Fe3O4 particles, we obtained a new generation magnetic-nano-scale polymer, magnetic-poly(HEMA–APH). This new molecule was chemically identified and approved by several characterization methods using Fourier transform infrared spectroscopy, scanning electron microscope, energy dispersive X-ray spectroscopy, electron spin resonance, atomic force microscope, and Zeta particle-size analysis. To evaluate the biological activity in live metabolism and anti-cancer potential of mag-poly(HEMA–APH), molecule was radioiodinated by a widely used labeling technique, iodogen method, with a gamma diffuser radionuclide, 131I. Thin-layer radiochromatography experiments demonstrated that 131I binded to nanopolymer with the labeling yield of 90 %. Lipophilicity and stability experiments were conducted to determine the condition of cold and labeled mag-poly(HEMA–APH) in rat blood and lipid medium. Results demonstrated that radioiodinated molecule stayed as an intact complex in rat metabolism for 24 h and experimental lipophilicity was determined as 0.12 ± 0.02. In vivo results obtained by imaging and biological distribution experiments indicated that mag-poly(HEMA–APH) labeled with 131I [131I-mag-poly(HEMA–APH)] highly incorporated into tissues of the uterus, the ovarian, the prostate, and the lungs in rat metabolism. Based on these results, it may be evaluated that novel mag-poly(HEMA–APH) molecule labeled with 131I is a compound which has a significant potential for being used as an anti-cancer agent. Certain results can only be obtained whether this molecule is applied to adenocarcinoma cell models and tumor-bearing animals.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Radiation Therapy and Dosimetry · Atomic and Subatomic Physics Research · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Akgöl S, Bereli N, Denizli A (2005) Magnetic dye affinity beads for the adsorption of β-casein. Macromol Biosci 5:786–79410.1002/mabi.200400230 ↗
2. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60(23):6641–6648
3. Alexiou C, Bergemann C, Schmid R, Hulin P, Schmidt A, Jurgons R, Arnold W, Parak FG (2002) Enrichment and biodistribution of a magnetically targeted drug carrier. Eur Cell Mater 3:135–137
4. Amin A, Gouda A, El-Sheikh R, Seddik U, Hussien H (2009) Radioiodination, purification and bioevaluation of piroxicam in comparison with meloxicam for imaging of inflammation. J Radioanal Nucl Chem 280(3):589–59810.1007/s10967-009-7483-9 ↗
5. Andrade JD (1976) Hydrogels for medical and related applications. ACS symposium series, vol. 31. American Chemical Society, Washington, DC10.1021/bk-1976-0031 ↗
6. Avcıbaşı U, Avcıbaşı N, Unak T, Ünak P, Müftüler FZB, Yıldırım Y, Dinçalp H, Gümüşer FG, Dursun ER (2008) Metabolic comparison of radiolabeled aniline- and phenol-phthaleins with 131I. Nucl Med Biol 35(4):481–49210.1016/j.nucmedbio.2008.02.003 ↗
7. Avcıbaşı U, Demiroğlu H, Ünak P (2010) In vivo biodistribution of 131I labeled Bleomycin (BLM) and isomers (A2 and B2) on experimental animal models. J Radioanal Nucl Chem 285:207–21410.1007/s10967-010-0565-x ↗
8. Avcıbaşı U, Demiroğlu H, Ediz M, Akalın HA, Özçalışkan E, Şenay H, Türkcan C, Özcan Y, Akgöl S, Avcıbaşı N (2013) Radiolabeling of new generation magnetic poly(HEMA–MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar Rats. J Label Compd Radiopharm. doi: 10.1002/jlcr.310810.1002/jlcr.3108 ↗
9. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K (2005) Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol Bio Syst 1:242–250
10. Baker JR, Quintana A Jr, Pehlerel L, Banazak-Holl al M, Tomalia D, Raczka E (2001) The synthesis and testing of anti-cancer therapeutic nanodevices. Biomed Microdevices 3(1):61–6910.1023/A:1011485622697 ↗
11. Balivada S, Rachakatla RS, Wang H, Samarakoon TN, Dani RK, Pyle M, Kroh FO, Walker B, Leaym X, Koper OB, Tamura M, Chikan V, Bossman SH, Troyer DL (2010) A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer 10:119–12710.1186/1471-2407-10-119 ↗
12. Bawa R (2007) Patents and nanomedicine. Nanomed Nanotech Biol Med 2:351–374
13. Berry CC, Curtis ASG (2003) Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 36:198–20610.1088/0022-3727/36/13/203 ↗
14. Borgman MP, Aras O, Geyser-Stoops S, Sausville EA, Ghandehari H (2009) Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. Mol Pharm 6(6):1836–184710.1021/mp900134c ↗
15. Boyle P, Levin B (2008) World cancer report. World Health Organization Press, Geneva
16. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuiller A, Khayat D (2002) Changing patient perceptions of side effects of cancer chemotherapy. Cancer 95:155–16310.1002/cncr.10630 ↗
17. Chappard D, Filmon R, Grizon F, Basle MF (2002) Effects of negatively charged groups (carboxymethyl) on the calcification of poly(2-hydroxyethyl methacrylate). Biomaterials 23:3053–305910.1016/S0142-9612(02)00069-8 ↗
18. Cheng F-Y, Su C-H, Yang Y-S, Yeh C-S, Tsai C-H, Wu C-L, Wu M-T, Shieh D-B (2005) Characterization of aqueous dispersions of Fe3O4 nanoparticles and their biomedical applications. Biomaterials 26:729–73810.1016/j.biomaterials.2004.03.016 ↗
19. Chunfu Z, Jinquan C, Duanzhi Y, Yongxian W, Yanlin F, Jiaju T (2004) Preparation and radiolabeling of human serum albumin (HSA)-coated magnetite nanoparticles for magnetically targeted therapy. Appl Radiat Isot 61:1255–125910.1016/j.apradiso.2004.03.114 ↗
20. Colak DG, Cianga I, Demirkol D, Kozgus O, Medine EI, Sakarya S, Ünak P, Timur S, Yağcı Y (2012) The synthesis and targeting of PPP-type copolymers to breast cancer cells: multifunctional platforms for imaging and diagnosis. J Mater Chem 22:9293–930010.1039/c2jm30692a ↗
21. Cole AJ, David AE, Wang J, Galban CJ, Hill HL, Yang VC (2011) Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials 8(32):2183–219310.1016/j.biomaterials.2010.11.040 ↗
22. Connors TA, Whisson ME (1966) Cure of mice bearing advanced plasma cell tumours with Aniline Mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 210:866–86710.1038/210866b0 ↗
23. Convreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 27(7):1417–145010.1007/s11095-006-0284-8 ↗
24. Çorman ME, Öztürk N, Tüzmen N, Akgöl S, Denizli A (2010) Magnetic polymeric nanospheres as an immobilized metal affinity chromatography (IMAC) support for catalase. Biochem Eng J 49:159–16410.1016/j.bej.2009.11.002 ↗
25. Dandamudi S, Campbell RB (2007) The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28:4673–468310.1016/j.biomaterials.2007.07.024 ↗
26. Deacon SP, Apostolovic B, Carbajo RJ et al (2011) Polymer coiled-coil conjugates: potential for development as a new class of therapeutic ‘‘molecular switch’’. Biomacromolecules 12(1):19–2710.1021/bm100843e ↗
27. Demiroğlu H, Avcıbaşı U, Ünak P et al (2012) Radiolabeling of bleomycin-glucuronide with 131I and biodistribution studies using xenograft model of human colon tumor in Balb/C mice. Cancer Biother Radiopharm 27(6):371–38310.1089/cbr.2011.1157 ↗
28. Dilnawaz F, Singh A, Mohanty C, Sahoo SK (2010) Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–370610.1016/j.biomaterials.2010.01.057 ↗
29. Dobic SN, Filipovic JM, Tomic SL (2012) Synthesis and characterization of poly(2-hydroxyethyl methacrylate/itaconic acid/poly(ethylene glycol) dimethacrylate) hydrogels. Chem Eng J 179:372–38010.1016/j.cej.2011.10.083 ↗
30. Dobson J (2006) Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther 13:283–28710.1038/sj.gt.3302720 ↗
31. Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discovery 2:347–36010.1038/nrd1088 ↗
32. Duncan R, Gilbert HRP, Carbajo RJ, Vicent MJ (2008) Polymer Masked-Unmasked Protein Therapy (PUMPT). 1. Bioresponsive dextrin-trypsin and -MSH conjugates designed for d-amylase activation. Biomacromolecules 9:1146–115410.1021/bm701073n ↗
33. Durner J, Kreppel H, Zaspel J, Schweilk H, Hickel R, Reichl F-X (2009) The toxicokinetics and distribution of 2-hydroxyethyl methacrylate in mice. Biomaterials 30(11):2066–207110.1016/j.biomaterials.2008.12.061 ↗
34. Ediz M, Avcıbaşı U, Ünak P et al (2013) Investigation of therapeutic efficiency of bleomycin and bleomycin-Glucuronide labeled with 131I on the cancer cell lines. Cancer Biother Radiopharm 28(4):310–31910.1089/cbr.2012.1316 ↗
35. Ferguson LR, Liu AP, Denny WA, Cullinane C, Talarico T, Phillips DR (2000) Transcriptional blockages in a cell-free system by sequenceselective DNA alkylating agents. Chem-Biol Interact 126(1):15–3110.1016/S0009-2797(00)00144-7 ↗
36. Ferlin MG, Dalla Via L, Gia OM (2004) Synthesis and antiproliferative activity of some new DNA-targeted alkylating pyrroloquinolines. Bioorgan Med Chem 12(4):771–77410.1016/j.bmc.2003.10.057 ↗
37. Fuchigami T, Kawamura R, Kitamoto Y, Nakagawa M, Namiki Y (2012) A magnetically guided anti-cancer drug delivery system using porous FePt capsules. Biomaterials 33:1682–168710.1016/j.biomaterials.2011.11.016 ↗
38. Gaihre B, Khil MS, Kim HY (2011) In vitro anticancer activity of doxorubicin-loaded gelatin-coated magnetic iron oxide nanoparticles. J Microencapsul 28(4):286–29310.3109/02652048.2011.559286 ↗
39. Gaspar R, Duncan R (2009) Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev 61(13):1220–123110.1016/j.addr.2009.06.003 ↗
40. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad OC (2007) Targeted nanoparticles for cancer therapy. Nanotoday 2:14–21
41. Hafeli UO (2004) Magnetically modulated therapeutic systems. Int J Pharm 277:19–2410.1016/j.ijpharm.2003.03.002 ↗
42. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26(1):57–6410.1016/j.urolonc.2007.03.015 ↗
43. Hsiue G-H, Guu J-A, Cheng- C-C (2001) Poly(2-hydroxyethyl methacrylate) film as a drug delivery system for pilocarpine. Biomaterials 22:1763–176910.1016/S0142-9612(00)00336-7 ↗
44. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, Chang YH, Chuang HC, Pang ST (2010) Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials 31:7355–736310.1016/j.biomaterials.2010.05.061 ↗
45. Huang C, Neoh KG, Xu L, Kang ET, Chiong E (2012) Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules 13:2513–252010.1021/bm300739w ↗
46. Hubacher MH (1951) Anilinephthalein. Notes 73:5885–5886
47. İçhedef Ç, Teksöz S, Ünak P, Medine Eİ, Ertay T, Bekiş R (2012) Preparation and characterization of radiolabeled magnetic nanoparticles as an imaging agent. J Nanopart Res 14:107710.1007/s11051-012-1077-0 ↗
48. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol 93:200–208
49. Jedlovszky-Hajdu A, Tombacz E, Banyai I, Babos M, Palko A (2012) Carboxylated magnetic nanoparticles as MRI contrast agents: relaxation measurements at different field strengths. J Magn Magn Mater 324:3173–318010.1016/j.jmmm.2012.05.031 ↗
50. Kayal S, Ramanujan RV (2010) J Nanosci Nanotechnol 10:5527–553910.1166/jnn.2010.2461 ↗
51. Khandare J, Minko T (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31:359–39710.1016/j.progpolymsci.2005.09.004 ↗
52. Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 44(10):853–86210.1021/ar2000277 ↗
53. Kim KY (2007) Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine 3(2):103–11010.1016/j.nano.2006.12.002 ↗
54. Koçan F, Avcıbaşı U, Ünak P et al (2011) Metabolic comparison of radiolabeled bleomycin and bleomycin-glucuronide labeled with 99mTc. Cancer Biother Radiopharm 26(5):573–58410.1089/cbr.2011.0998 ↗
55. Kong SD, Zhang W, Lee JH, Brammer K, Lal R, Karin M, Jin S (2010) Magnetically vectored nanocapsules for tumor penetration and remotely switchable on-demand drug release. Nano Lett 10(12):5088–509210.1021/nl1033733 ↗
56. Kumar B, Yadav PR, Goel HC, Moshahid M, Rizvi A (2009) Recent developments in cancer therapy by the use of nanotechnology. Digest J Nanomater Biostr 4(1):1–1210.1155/2009/728957 ↗
57. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, Sajjad M, Prasad PN (2010) In vivo biodistribution and clearance studies using multimodal ORMOSIL nanoparticles. ACS Nano 4(2):699–70810.1021/nn901146y ↗
58. LaConte L, Nitin N, Bao G (2005) Magnetic nanoparticle probes. Nanotoday 8:32–38
59. Lammers T (2009) Drug targeting to tumors using HPMA copolymers. Dissertation, Utrecht University
60. Lammers T, Kühnlein R, Kissel M et al (2005) Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release 110(1):103–11810.1016/j.jconrel.2005.09.010 ↗
61. Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P, Hennink W, Storm G (2006) Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer–based drug delivery systems. Neoplasia 8(10):788–79510.1593/neo.06436 ↗
62. Lammers T, Subr V, Ulbrich K, Peschke P, Huber PE, Hennink WE, Storm G (2009) Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30:3466–347510.1016/j.biomaterials.2009.02.040 ↗
63. Larson N, Ghandehari H (2012) Polymeric conjugates for drug delivery. Chem Mater 24(5):840–85310.1021/cm2031569 ↗
64. Larson N, Ray A, Malugin A, Pike DB, Ghandehari H (2010) HPMA copolymer-aminohexylgeldanamycin conjugates targeting cell surface expressed GRP78 in prostate cancer. Pharm Res 27(12):2683–269310.1007/s11095-010-0267-7 ↗
65. Liang S, Wang Y, Yu J, Zhang C, Xia J, Yin D (2007) Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy. J Mater Sci Mater Med 18:2297–230210.1007/s10856-007-3130-6 ↗
66. Liao Z, Wang H, Wang X, Wang C, Hu X, Cao X, Chang J (2010) Biocompatible surfactin-stabilized superparamagnetic iron oxide nanoparticles as contrast agents for magnetic resonance imaging. Colloids Surf A Physicochem Eng Asp 370:1–510.1016/j.colsurfa.2010.06.025 ↗
67. Lin SY, Hsu WH, Lo JM, Tsai HC, Hsiue GH (2011) Novel geometry type of nanocarriers mitigated the phagocytosis for drug delivery. J Control Relase 154(1):84–9210.1016/j.jconrel.2011.04.023 ↗
68. Ma X, Wang H, Jin S, Wu Y, Liang X-J (2012) Construction of paclitaxel-loaded poly(2-hydroxyethylmethacrylate)-g-poly(lactide)-1,2-dipalmitoyl-sn-glycero-3-hosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity. Int J Nanomed 7:1313–1328
69. Masoudi A, Hosseini HRM, Shokrgozar MA, Ahmadi R, Oghabian MA (2012) The effect of poly(ethylene glycol) coating on colloidal stability of superparamagnetic iron oxide nanoparticles as potential MRI contrast agent. Int J Pharm 433:129–14110.1016/j.ijpharm.2012.04.080 ↗
70. Medeiros SF, Santos AM, Fessi H, Elaissari A (2011) Stimuli-responsive magnetic particles for biomedical applications. Int J Pharm 403:139–16110.1016/j.ijpharm.2010.10.011 ↗
71. Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R (2009) Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 48(16):2949–295410.1002/anie.200805133 ↗
72. Montheard JP, Chatzopoulos M, Chappard D (1992) 2-hydroxyethyl methacrylate (HEMA); chemical properties and applications in biomedical fields. J Macromol Sci Macromol Rev 32:16–21
73. Nguyen H-N, Wey S-P, Juang J-H, Ho Y-C, Sonaje K, Chuang E-Y, Hsu C-W, Yen T-C, Lin K-J, Sung H-W (2011) The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32:2673–268210.1016/j.biomaterials.2010.12.044 ↗
74. Nie S, Xing Y, Kim GJ, Simons JW (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9:257–28810.1146/annurev.bioeng.9.060906.152025 ↗
75. Nita LE, Chiriac AP, Nistor MT, Tartau L (2012) Indomethacin uptake into poly(2-hydroxyethyl methacrylate-co-3,9-divinyl-2, 4,8,10-tetraoxaspiro [5.5]-undecane) network: in vitro and in vivo controlled release study. Int J Pharm 426:90–9910.1016/j.ijpharm.2012.01.028 ↗
76. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307–31410.1111/j.1349-7006.1998.tb00563.x ↗
77. O’connor R (2007) The pharmacology of cancer resistance. Anticancer Res 27:1267–1272
78. Pal D, Nayak AK (2010) Nanotechnology for targeted delivery in cancer therapeutics. Int J Pharm Sci Rev Res 1(1):1–7
79. Pankhurst QA, Connolly J, Jones SK, Dobson J (2003) Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 36:167–18110.1088/0022-3727/36/13/201 ↗
80. Pasut G, Veronese FM (2007) Polymer drug conjugation, recent achievements and general strategies. Prog Polym Sci 32:933–96110.1016/j.progpolymsci.2007.05.008 ↗
81. Pautler M, Brenner S (2010) Nanomedicine: promises and challenges for the future of public health. Int J Nanomed 5:803–809
82. Perçin I, Karakoç V, Akgöl S, Aksöz E, Denizli A (2012) Poly(hydroxyethyl methacrylate) based magnetic nanoparticles for plasmid DNA purification from Escherichia coli lysate. Mater Sci Eng 32:1133–114010.1016/j.msec.2012.02.031 ↗
83. Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. Am J Roentgenol 71(5):826–834
84. Pike DB, Ghandehari H (2010) HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv Drug Deliv Rev 62:167–18310.1016/j.addr.2009.11.027 ↗
85. Pimm MV, Perkins AC, Duncan R, Ulbrich K (1993) Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J Drug Target 1(2):125–13110.3109/10611869308996068 ↗
86. Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R (1996) Gamma scintigraphy of the biodistribution of 123I-labeled N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Target 3(5):375–38310.3109/10611869608996828 ↗
87. Pliska V, Testa B, van de Waterbeemd H (1996) Lipophilicity and Biological Activity. In: Mannhold R, Kubinyi H, Timmerman H (eds) Lipophilicity in drug action and toxiocology. VCH, New York, pp 22–2610.1002/9783527614998 ↗
88. Prokes J, Cerný B, Vulterin K et al (1996) Distribution of 3H-labeled acetyl-HEMA monomer in rats. Sb Lek 97(4):449–454
89. Ramanujan RV, Chong WT (2004) The synthesis and characterization of polymer coated iron oxide microspheres. J Mater Sci Mater Med 15:901–90810.1023/B:JMSM.0000036278.09272.97 ↗
90. Reichl FX, Durner J, Kehe K et al (2002) Toxicokinetic of HEMA in guinea pigs. J Dent 30(7):353–35810.1016/S0300-5712(02)00050-7 ↗
91. Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polym Sci Symp 51:135–15310.1002/polc.5070510111 ↗
92. Rosen JE, Chan L, Shieh DB, Gu FX (2012) Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine 8:275–29010.1016/j.nano.2011.08.017 ↗
93. Ruiz A, Salas G, Calero M, Hernandez Y, Villanueva A, Herranz F, Veintemillas-Verdaguer S, Martinez E, Barber DF, Morales MP (2013) Short-chain PEG molecules strongly bound to magnetic nanoparticle for MRI long circulating agents. Acta Biomater 9:6421–643010.1016/j.actbio.2012.12.032 ↗
94. Sahu SK, Maiti S, Pramanik A, Ghosh SK, Pramanik P (2012) Controlling the thickness of polymeric shell on magnetic nanoparticles loaded with doxorubicin for targeted delivery and MRI contrast agent. Carbohydr Polym 87:2593–260410.1016/j.carbpol.2011.11.033 ↗
95. Saiyed ZM, Telang SD, Ramchand CN (2003) Application of magnetic techniques in the field of drug discovery and biomedicine. Biomagn Res Technol 1:1–810.1186/1477-044X-1-2 ↗
96. Schuster GS, Caughman GB, Rueggeberg FA (2000) Changes in cell phospholipid metabolism in vitro in the presence of HEMA and its degradation products. Dent Mater 16(4):297–30210.1016/S0109-5641(00)00022-1 ↗
97. Segal E, Satchi-Fainaro R (2009) Design and development of polymer conjugates as anti-angiogenic agents. Adv Drug Deliv Rev 61(13):1159–117610.1016/j.addr.2009.06.005 ↗
98. Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, Wang J, Tang J, Fan M, Van Kirk E, Murdoch WJ (2010) Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J Am Chem Soc 32(12):4259–426510.1021/ja909475m ↗
99. Shieh D-B, Cheng F-Y, Su C-h, Yeh C-S, Wu M-T, Wu Y-N, Tsai C-Y, Wu C-L, Chen D-H, Chou C-H (2005) Aqueous dispersions of magnetite nanoparticles with NH3+ surfaces for magnetic manipulations of biomolecules and MRI contrast agents. Biomaterials 26:7183–719110.1016/j.biomaterials.2005.05.020 ↗
100. Strauss HW, Nunn A, Linder K (1995) Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 2(5):437–44510.1016/S1071-3581(05)80031-5 ↗